How we can stop neurons from dying is an enormous problem
At Yale School of Medicine, scientists have identified two proteins — mGluR4 and NPDC1 — that serve as unwitting accomplices in Parkinson's disease, ferrying toxic, misfolded proteins from dying neurons into healthy ones and deepening the brain's slow unraveling. Published in Nature Communications, the discovery emerges from a painstaking search through 4,400 candidate proteins, guided by the long-held but poorly understood observation that Parkinson's spreads like a kind of biological contagion. For the 1.1 million Americans living with the disease, and the aging populations who will follow, this finding offers something medicine has rarely been able to promise: not just relief from suffering, but a possible way to interrupt its cause.
- Parkinson's disease has long outpaced medicine's ability to fight it — current treatments ease tremors and stiffness but do nothing to stop the neurons quietly dying underneath.
- The missing piece was the mechanism: how does a toxic, misfolded protein escape a dying cell and invade a healthy one, spreading destruction deeper into the brain?
- Yale researchers screened 4,400 different surface proteins in a systematic hunt, and two — mGluR4 and NPDC1 — emerged as the transporters enabling this cellular invasion.
- In mouse studies, animals engineered without these proteins were shielded from toxic buildup and Parkinson's-like symptoms, even after direct exposure to misfolded α-synuclein.
- With nearly 90,000 new American diagnoses each year and an aging population swelling the risk pool, the pressure to translate this discovery into disease-slowing therapies is intensifying.
A Yale School of Medicine team has identified two proteins that appear to act as entry points, allowing a toxic misfolded protein to cross from dying neurons into healthy ones and advance Parkinson's disease deeper into the brain. The discovery, published in Nature Communications, opens a path toward treatments that might slow the disease itself — not merely soften its symptoms.
Parkinson's destroys neurons gradually, driven by the accumulation of a protein called α-synuclein that folds incorrectly and becomes toxic. Scientists have long known this damage spreads through the brain, but the precise mechanism — how the toxic protein breaches healthy cells — remained elusive, limiting treatment to symptom management.
Neuroscience chair Stephen Strittmatter led a methodical search, engineering 4,400 groups of cells each displaying a different surface protein, then exposing them to misfolded α-synuclein to see what bound. Of 16 proteins that interacted with the toxic agent, two stood out: mGluR4 and NPDC1. Both are found on dopamine-producing neurons in the substantia nigra, the brain region most ravaged by Parkinson's — and both were not merely binding to α-synuclein, but transporting it inside.
Mouse experiments confirmed the significance. Animals genetically lacking either protein were exposed to misfolded α-synuclein but showed no toxic buildup and no Parkinson's-like symptoms. In a separate Parkinson's disease model, removing either gene slowed symptom progression and reduced mortality — a striking contrast to untreated animals.
The stakes are considerable. Parkinson's affects roughly 1.1 million Americans, with nearly 90,000 new diagnoses annually, and the disease strikes hardest among older adults — a population set to grow sharply in coming decades. Strittmatter put the challenge directly: figuring out how to slow neuronal death is an enormous problem, and now, for the first time, researchers have a concrete molecular target to pursue.
A team at Yale School of Medicine has identified two proteins that appear to act as gatekeepers, allowing a toxic, misfolded protein to invade healthy brain cells and spread Parkinson's disease deeper into the brain. The discovery, published in Nature Communications, points toward a fundamentally different approach to treating the disease—not just managing tremors and stiffness, but potentially stopping the disease's progression at its source.
Parkinson's disease kills neurons gradually. The hallmark of this destruction is the accumulation of a protein called α-synuclein that folds incorrectly, becoming toxic. As these misfolded proteins escape from dying neurons and move into healthy ones, the disease worsens. For decades, researchers understood that this spread was happening, but not exactly how the toxic protein crossed the barrier into new cells. That gap in understanding has limited treatment options. Current medications help people manage symptoms—reduce tremors, improve movement—but they do not slow the underlying damage.
Stephen Strittmatter, chair of neuroscience at Yale, led a systematic hunt for the answer. His team engineered 4,400 different groups of cells, each displaying a different surface protein. They then exposed these cells to misfolded α-synuclein and watched to see what stuck. Most proteins showed no interaction. But 16 did bind to the toxic protein. Two of them—mGluR4 and NPDC1—stood out. Both are found on dopamine-producing neurons in the substantia nigra, the exact brain region most damaged in Parkinson's disease. The researchers realized these proteins were not just binding to α-synuclein; they were transporting it into the cells.
To test whether blocking these transporters could stop the disease, the team turned to mice. They genetically removed the genes for either mGluR4 or NPDC1, then exposed the animals to misfolded α-synuclein. Normal mice developed toxic protein buildup in their brains and went on to show Parkinson's-like symptoms. The engineered mice—those lacking functional versions of either protein—did not. In a separate mouse model of Parkinson's disease itself, removing either gene slowed symptom progression and reduced the risk of death.
The implications are significant. If these proteins truly act as transporters, blocking them could become a new class of therapy. Rather than treating the symptoms of a disease that continues to advance, doctors might be able to slow or even halt the spread of the toxic protein itself. Strittmatter notes that existing treatments do not significantly slow the underlying disease, only manage its effects.
The timing matters. Parkinson's disease affects roughly 1.1 million Americans, with nearly 90,000 new diagnoses each year. The disease primarily strikes older adults, and as the population over 65 grows substantially in the coming decades, the number of people at risk will rise sharply. The need for treatments that actually slow the disease, rather than simply ease its symptoms, will become more urgent. Strittmatter frames the challenge plainly: "How we can stop or slow neurons from dying is an enormous problem. This is really the time to make some inroads into figuring out how to slow it down." The discovery of mGluR4 and NPDC1 as critical transporters gives researchers a concrete target to pursue.
Citas Notables
If we understood how it gets into neurons, we could perhaps block or slow down the progression of the disease.— Stephen Strittmatter, Yale School of Medicine
La Conversación del Hearth Otra perspectiva de la historia
So they found two proteins that let the bad protein in. But how did they know to look for proteins on the cell surface in the first place?
They suspected that α-synuclein had to attach to something on the outside of healthy neurons before it could get inside. It's like a lock-and-key problem. So instead of guessing, they built 4,400 different locks and tested which ones the toxic protein would fit into.
That's a lot of cells to engineer. Why not just test a few?
Because they didn't know which proteins mattered. Testing thousands was the only way to be thorough. And it paid off—they found 16 proteins that bound to α-synuclein, but only two seemed to actually transport it inside.
And then they tested blocking those proteins in mice?
Yes. They removed the genes for mGluR4 or NPDC1 and exposed the mice to the misfolded protein. The normal mice got sick. The engineered mice didn't.
That sounds like a cure.
Not quite. It works in mice. Whether it will work in humans is still unknown. But it's the first time anyone has shown you can prevent the spread by blocking these specific transporters. That's the door opening.
Why does it matter that these proteins are on dopamine neurons specifically?
Because that's where Parkinson's hits hardest. The substantia nigra is the brain region most affected by the disease. Finding that the transporters are right there, in the cells being destroyed, suggests they're not just involved—they might be essential to how the disease spreads in the first place.